. 2019 Feb 22;3(4):612–620. doi: 10.1182/bloodadvances.2018029199

Table 1.

Baseline characteristics of adolescents and adults with newly diagnosed BL in Lilongwe, Malawi, from 2013 to 2018

	Total no. of patients	All						HIV-positive (n = 15)						HIV-negative (n = 20)						P
	Total no. of patients	No.	%	Median	Range	Mean	SD	No.	%	Median	Range	Mean	SD	No.	%	Median	Range	Mean	SD	P
Male sex	35	25	71					10	67					15	75					.71
Age, y	35			21	15-61					40	21-61					15	15-41			<.001
Body mass index, kg/m²	30					19.1	4.5					21.8	3.1					16.2	3.9	<.001
B symptoms	35	24	69					10	67					14	70					1
Ann Arbor stage III to IV	35	27	77					9	60					18	90					.05
ECOG PS ≥2	35	19	54					5	33					14	70					.04
aaIPI	32																			.28
0		1	3					1	7					0	0
1		7	22					5	33					2	12
2		12	38					5	33					7	41
3		12	38					4	27					8	47
Central nervous system involvement	35	5	14					1	7					4	20					.36
Bone marrow involvement	22	4	18					2	50					2	15					1.00
Abdominal disease	35	23	66					7	47					16	80					.07
Bulky disease (>10 cm)	24	16	66					9	60					7	78					.66
HIV diagnosis known prior to Burkitt diagnosis	15	―						9	60					―						―
Time since HIV diagnosis, years	9		―							1.4	0.4-9.4				―					―
Receiving ART at BL diagnosis	15	―						8	53					―						―
Duration of ART at BL diagnosis, years	8		―							1.1	0.4-2.6				―					―
CD4 count, cells per μL	15		―							130	29-605				―					―
HIV viral load, log₁₀ copies per μL	15		―							1.6	0-6.0				―					―
HIV viral load, detectable >400 copies per μL	15	―						5	33					―						―
White blood cells, ×10⁹/L	35			7.2	2.1-20.3					4.8	2.1-12.0					8.3	3.6-20.3			.005
Hemoglobin, g/dL	35			10.8	1.6-14.8					11.0	7.7-14.8					9.8	1.6-14.3			.17
Platelets, ×10⁹/L	35			365	77-859					312	77-791					382	139-859			.44
Creatinine, mg/dL	33			0.6	0.3-28.0					0.8	0.6-28.0					0.5	0.3-11.4			.002
Bilirubin, mg/dL	32			0.3	0.2-2.0					0.3	0.2-1.4					0.4	0.2-2.0			.05
Albumin, g/dL	26					3.7	0.8					3.8	0.8					3.6	0.9	.69
LDH ratio per ULN	32			2.2	0.4-22.3					3.0	0.7-22.3					2.1	0.4-20.0			.35
LDH >2× ULN	32	22	67					11	73					11	65					.71
EBER positive by in situ hybridization	19	9	47					2	20					7	78					.02
First-line chemotherapy	31																			1.00
CHOP		22	71					9	75					13	68
More intensive		9	29					3	25					6	32

aaIPI, age-adjusted International Prognostic Index; EBER, Epstein-Barr virus–encoded RNA; SD, standard deviation.